JP2024539735A5 - - Google Patents

Info

Publication number
JP2024539735A5
JP2024539735A5 JP2024529362A JP2024529362A JP2024539735A5 JP 2024539735 A5 JP2024539735 A5 JP 2024539735A5 JP 2024529362 A JP2024529362 A JP 2024529362A JP 2024529362 A JP2024529362 A JP 2024529362A JP 2024539735 A5 JP2024539735 A5 JP 2024539735A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
administered
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539735A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/050163 external-priority patent/WO2023091524A1/en
Publication of JP2024539735A publication Critical patent/JP2024539735A/ja
Publication of JP2024539735A5 publication Critical patent/JP2024539735A5/ja
Pending legal-status Critical Current

Links

JP2024529362A 2021-11-16 2022-11-16 治療用化合物 Pending JP2024539735A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280067P 2021-11-16 2021-11-16
US63/280,067 2021-11-16
PCT/US2022/050163 WO2023091524A1 (en) 2021-11-16 2022-11-16 Therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2024539735A JP2024539735A (ja) 2024-10-29
JP2024539735A5 true JP2024539735A5 (cg-RX-API-DMAC7.html) 2025-12-02

Family

ID=86397745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529362A Pending JP2024539735A (ja) 2021-11-16 2022-11-16 治療用化合物

Country Status (5)

Country Link
US (1) US20250099483A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433062A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539735A (cg-RX-API-DMAC7.html)
IL (1) IL312745A (cg-RX-API-DMAC7.html)
WO (1) WO2023091524A1 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20110263569A1 (en) * 2007-08-22 2011-10-27 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
EP2708535A1 (en) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
WO2021222739A1 (en) * 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP2024519917A (ja) * 2021-05-20 2024-05-21 アームゴ・ファーマ・インコーポレーテッド リアノジン受容体モジュレーターを含む医薬組成物およびそれらの使用

Similar Documents

Publication Publication Date Title
US4248858A (en) Sustained release pharmaceutical compositions
RU2201754C2 (ru) Фармацевтический состав, способ его получения, способ лечения психотических состояний и гиперактивности
JP3745621B2 (ja) 持続放出型ラノラジン製剤
US6479496B1 (en) Methods for treating angina with ranolazine
US4248856A (en) Sustained release pharmaceutical compositions
TWI917329B (zh) 心臟肌小節抑制劑口服調配物
JP5344620B2 (ja) オルメサルタンメドキソミル及びアムロジピンの固形製剤
JP2008069159A5 (cg-RX-API-DMAC7.html)
US11819577B2 (en) Fixed dose pharmaceutical composition of valsartan and sacubitril
CN102056603A (zh) 决奈达隆用于预防持续性心房纤颤
US20080027032A1 (en) Combinations comprising cox-2 inhibitors and aspirin
JP2005255687A (ja) リゼドロネート遅延放出組成物
CN109890366A (zh) 治疗心血管疾病的组合药物及其制备和使用方法
NO342977B1 (no) Racecadotriltablett, fremgangsmåte for fremstilling av slike og slike tabletter for behandling av diaré
TW202423423A (zh) 治療非阻塞性肥厚性心肌病之方法
JP2022511788A5 (cg-RX-API-DMAC7.html)
CN102149377A (zh) 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途
WO2010009618A1 (zh) 用于治疗高血压和代谢综合症的药物组合物及其应用
EP1891937A1 (en) Galenic formulations of aliskiren
US6849661B2 (en) Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil
JP2024519917A5 (cg-RX-API-DMAC7.html)
CN102056602A (zh) 决奈达隆用于预防心脏复律
KR100623122B1 (ko) 조합 제제로서의 엔도텔린 길항제 및 베타-수용체 차단제
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии